TNF and ankylosis: The use of adalimumab as the first TNF-α inhibitor was less likely to lead to switching (HR 0.323, 95% Cl 0.134–0.779), whereas complete ankylosis evident on radiographs of the sacroiliac joint was more likely to lead to switching (HR 1.868, 95% Cl 1.128–3.095).